Joseph R. Anticaglia MD
Medical Advisory Board
The best chance for patience winning the battle against cancer, in addition to a healthy lifestyle, is early detection, and precise, treatment of this death-dealing disease. Liquid biopsy, (LB), is a term first used around 2010. It’s a blood test that detects and analyzes circulating tumor cells and their products released by cancer cells into the blood.
When cancer cells die, they are replaced with other cancer cells. The dead cancer cells scatter cancer-connected material into the bloodstream called circulating tumor DNA, ctDNA. The objective of scientists is to use blood samples to identify, treat and monitor cancer to better manage patients.
Presently, liquid biopsy doesn’t replace a tissue biopsy’s usefulness in diagnosing, and classifying tumors. But LB technology is making progress in detecting, characterizing, and managing cancer. There are notable advantages of LB.
Liquid biopsy is a non-invasive blood test that looks for abnormal genetic pieces of DNA from cancer cells, or their products in the bloodstream. Using this technology, clinicians aim to provide cancer patients with a personalized, targeted approach in the management of this deadly disease.
There are advantages to LB compared to tissue biopsy, but more research is needed to address the test’s limitations for it to become widely used in clinical practice; and as a screening test to identify cancer in individuals before symptoms, and signs appear.
A biomarker is a biological molecule used to diagnose a normal, or abnormal disease, condition, or process. It’s found in blood and tissues. urine, or other bodily fluids. There are different types of biomarkers.
ctDNA — circulating tumor DNA
cfDNA — Cell-free DNA
CTC — Circulating tumor cells
This article is intended solely as a learning experience. Please consult your physician for diagnostic and treatment options.